Hospira Inc (HSP.N)
42.03USD
1 Aug 2013
$1.33 (+3.27%)
$40.70
$41.05
$42.60
$41.03
411,379
238,445
$42.60
$28.63
About
Overall
| Beta: | 0.87 |
| Market Cap (Mil.): | $6,741.92 |
| Shares Outstanding (Mil.): | 165.65 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| HSP.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 37.93 | 37.76 |
| EPS (TTM): | -0.22 | -- | -- |
| ROI: | -1.29 | 19.48 | 18.76 |
| ROE: | -1.24 | 20.17 | 19.59 |
UPDATE 2-Regulators pave way for biosimilar drug breakthrough
LONDON/ZURICH June 28 - European regulators have cleared the way for the first serious threat to the makers of multibillion-dollar biotechnology drugs to treat diseases such as cancer and rheumatoid arthritis.
FDA raises drug safety concerns at Hospira facility in India
May 30 - Hospira Inc said it received a warning letter from the U.S. Food and Drug Administration raising concerns about contamination of drugs manufactured at its facility in India.
U.S. court ruling favors Cubist in patent case versus Hospira
- A federal court on Monday ruled in favor of Cubist Pharmaceuticals Inc on the interpretation of patent language in a case involving a generic challenge to its lead drug Cubicin by Hospira Inc .
U.S. court ruling favors Cubist in patent case vs Hospira
May 20 - A U.S. federal court on Monday ruled in favor of Cubist Pharmaceuticals Inc on the interpretation of patent language in a case involving a generic challenge to its lead drug Cubicin by Hospira Inc.
FDA flags new concerns on Hospira's Rocky Mount plant
- Hospira Inc said U.S. health regulators raised fresh concerns about the injectable-drugs maker's troubled Rocky Mount, North Carolina manufacturing plant - one of its largest production facilities.
Hospira withdraws outlook on FDA import ban, shares fall
- Injectable-drugs maker Hospira Inc withdrew the 2013 profit and revenue outlook it gave on Wednesday after the U.S. health regulator imposed an import ban on some of its products.
Hospira gets FDA notice over medical device problems
- Hospira Inc, a hospital products maker that has grappled with regulatory issues at manufacturing plants for the past 18 months, said it had received a notice over the quality of its medical devices from the U.S. Food and Drug Administration.
UPDATE 3-Hospira gets FDA notice over medical device problems
* Expects 2013 sales up 1 pct to 3 pct, adjusted diluted eps of $2.05-$2.20
Hospira swings to profit in fourth quarter as sales rise
Feb 13 - Injectable drug provider Hospira Inc on Wednesday reported a profit for the fourth quarter versus a year-earlier loss as its sales increased more than 8 percent.
Competitors
| Price | Change | |
|---|---|---|
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 13,920.00₪ | -200.00 |
| Baxter International Inc. (BAX.N) | $72.20 | -0.84 |
| CareFusion Corporation (CFN.N) | $38.95 | +0.38 |
| Fresenius Kabi Pharma. Holding Inc (APCVZ.OQ) | -- | -- |
| Mylan Inc. (MYL.OQ) | $33.99 | +0.43 |
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
| Sanofi SA (SASY.PA) | €76.85 | -3.32 |
| Terumo Corp (4543.T) | ¥5,070 | -30.00 |
| Intas Pharmaceuticals Ltd (IPO-INTA.NS) | -- | -- |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (HSP). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

